NCT05460273 · OUTCOME

Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Dato-DXd

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · Source last updated 2026-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: h
Interval / dispersion: Full Range
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

What was measured

Time to maximum plasma concentration

Analysis population: PK analysis set: Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.

Groups in this outcome

TNBC Cohort

Final Analysis with DCO on 06May2024

NSCLC Cohort

Final Analysis with DCO on 27Nov2024

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
TNBC Cohort	8
NSCLC Cohort	9

Reported measurements

Source class 1

Values in h · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
TNBC Cohort	4.95	Not reported	1.83	7.17	Not reported
NSCLC Cohort	1.63	Not reported	1.38	5.22	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
1.83
upper Limit
7.17
value
4.95
group Id
OG001
lower Limit
1.38
upper Limit
5.22
value
1.63

denoms

counts
group Id
OG000
value
8
group Id
OG001
value
9
units
Participants

description

Time to maximum plasma concentration

dispersion Type

Full Range

groups

description
Final Analysis with DCO on 06May2024
id
OG000
title
TNBC Cohort
description
Final Analysis with DCO on 27Nov2024
id
OG001
title
NSCLC Cohort

param Type

MEDIAN

population Description

PK analysis set: Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.

reporting Status

POSTED

time Frame

TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

title

Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Dato-DXd

type

SECONDARY

unit Of Measure

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice